To include your compound in the COVID-19 Resource Center, submit it here.

CAR T confidence

How China’s JW leveraged growing enthusiasm for CAR T to raise $90M series A

The first CAR T therapy approvals in the U.S. followed by CFDA guidelines on cell therapy development and manufacturing gave a boost to Chinese investor interest in the space, enabling JW Therapeutics (Shanghai) Co. Ltd. to raise a $90 million series A round.

Temasek, Sequoia Capital

Read the full 450 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE